Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Phase 1
- Conditions
- Advanced Cancer
- Interventions
- Drug: ZIO-101-C (Darinaparsin)
- Registration Number
- NCT00591422
- Lead Sponsor
- Alaunos Therapeutics
- Brief Summary
The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single Arm ZIO-101-C (Darinaparsin) -
- Primary Outcome Measures
Name Time Method Toxicities 6 months
- Secondary Outcome Measures
Name Time Method pharmacokinetics 6 months